NeoGenomics (NASDAQ: NEO) director receives new RSU and stock option grants

Rhea-AI Filing Summary

NEOGENOMICS INC director Carolyn S. Starrett reported receiving new equity awards. On 2026-06-23, she was granted 14,125 Restricted Stock Units, each representing one share of common stock when vested. She was also granted stock options for 9,784 shares of common stock at an exercise price of $11.20 per share, expiring on 2036-06-01. A footnote states that once vested, the common shares underlying these awards are not subject to expiration.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Starrett Carolyn S

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	9,784	$0.00	--
Grant/Award	Restricted Stock Unit	14,125	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 9,784 shares (Direct, null); Restricted Stock Unit — 14,125 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 14,125 units Option grant size: 9,784 options Option exercise price: $11.20 per share +3 more

6 metrics

RSU grant size 14,125 units Restricted Stock Units granted on 2026-06-23

Option grant size 9,784 options Stock Option (Right to Buy) granted on 2026-06-23

Option exercise price $11.20 per share Conversion or exercise price for stock options

Option expiration 2036-06-01 Expiration date for stock options

RSU underlying shares 14,125 shares Common stock underlying RSU award

Options underlying shares 9,784 shares Common stock underlying option award

Key Terms

Restricted Stock Unit, Stock Option (Right to Buy), exercise price, expiration date

4 terms

Restricted Stock Unit financial

"she was granted 14,125 Restricted Stock Units, each representing one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Stock Option (Right to Buy) financial

"She was also granted stock options for 9,784 shares of common stock"

exercise price financial

"stock options for 9,784 shares of common stock at an exercise price of $11.20 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"stock options for 9,784 shares of common stock at an exercise price of $11.20 per share, expiring on 2036-06-01"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/25/2026 - 04:10 PM Accepted by SEC EDGAR 06/25/2026 - 04:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Starrett Carolyn S

(Last) (First) (Middle)

9490 NEOGENOMICS WAY

(Street)

FORT MYERS FLORIDA 33912

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEOGENOMICS INC [ NEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.2	06/23/2026		A		9,784		06/01/2027	06/01/2036	Common Stock	9,784	$0	9,784	D
Restricted Stock Unit	$0	06/23/2026		A		14,125		06/01/2027	(1)	Common Stock	14,125	$0	14,125	D

Explanation of Responses:

1. Once vested, the shares of common stock are not subject to expiration.

Remarks:

	/s/ Ali Olivo, Attorney-in-Fact	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did NEOGENOMICS INC (NEO) report for Carolyn S. Starrett?

NEOGENOMICS INC reported that director Carolyn S. Starrett received two equity awards on 2026-06-23. She was granted 14,125 Restricted Stock Units and stock options for 9,784 shares of common stock at an exercise price of $11.20 per share.

How many Restricted Stock Units did Carolyn S. Starrett receive at NEO?

Carolyn S. Starrett received 14,125 Restricted Stock Units from NEOGENOMICS INC on 2026-06-23. Each RSU represents one share of common stock upon vesting, and once vested, the underlying common shares are not subject to expiration according to the footnote.

What are the key terms of Carolyn S. Starrett’s new stock options at NEOGENOMICS INC?

Starrett was granted stock options covering 9,784 shares of NEOGENOMICS INC common stock on 2026-06-23. The options have an exercise price of $11.20 per share and an expiration date of 2036-06-01, with underlying common shares not expiring once vested.

Are Carolyn S. Starrett’s new NEOGENOMICS equity awards open-market purchases or compensation grants?

The Form 4 classifies both transactions with code “A,” described as a grant, award, or other acquisition. This indicates the 14,125 RSUs and 9,784 stock options were awarded to Carolyn S. Starrett, rather than acquired through open-market purchases of NEOGENOMICS INC stock.

Does Carolyn S. Starrett hold these NEOGENOMICS equity awards directly or indirectly?

The filing lists both the 14,125 Restricted Stock Units and the 9,784 stock options as directly owned by Carolyn S. Starrett. The ownership code is “D” for direct, and there is no footnote indicating that another entity holds voting or investment authority.